Ziftomenib with venetoclax and azacitidine in relapsed/refractory NPM1-mutated acute myeloid leukemia
Eunice S. Wang(Roswell Park Comprehensive Cancer Center), Ghayas C. Issa(The University of Texas MD Anderson Cancer Center), Tara L. Lin(Dana-Farber Cancer Institute), Ayman Qasrawi(University of Kentucky), Ivana Gojo(Johns Hopkins University), GJ Schiller(University of California, Los Angeles), Christine M. McMahon(Albert Einstein College of Medicine), Amir Fathi(Massachusetts General Hospital), Anjali S. Advani(Cleveland Clinic), Suresh Kumar Balasubramanian(Cleveland Clinic), Yazan F. Madanat(The University of Texas Southwestern Medical Center), Jessica Altman(Northwestern University), Marcello Rotta(Colorado Blood Cancer Institute), Talha Badar(Jacksonville College), Stephen A. Strickland(Centennial Medical Center), Guru Subramanian Guru Murthy(Medical College of Wisconsin), Daniel Corum(Kura Oncology (United States)), James McCloskey(Hackensack University Medical Center), Amer M. Zeidan(Yale University), Kiran Naqvi(University of California, Irvine Medical Center), Harris S. Soifer(Kura Oncology (United States)), Harry P. Erba(Duke University), Mark B. Juckett(University of Minnesota System), Mollie Leoni(Kura Oncology (United States)), Gail J. Roboz(Cornell University), Hongling Zhang(Kura Oncology (United States)), Antoine N Saliba(Mayo Clinic), Diaa Osman(Texas Oncology), Keith W. Pratz(University of Pennsylvania), Ying Tian(Kura Oncology (United States)), Mohamad Khawandanah(University of Oklahoma Health Sciences Center), Marcie Riches(Kura Oncology (United States)), Leonard Clarkson Alsfeld(Ochsner Health System), George Yaghmour(University of Tennessee Health Science Center), Neil Palmisiano(Rutgers, The State University of New Jersey), James K. Mangan(UC San Diego Health System)
Cited by 0
Related Papers
Inotuzumab ozogamicin, an anti-CD22–calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study
|The Lancet Oncology|2012|411
Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse
|Blood|2011|402
Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide
|Blood|2015|299
Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic Leukemia
|Journal of Clinical Oncology|2019|274